Invention Grant
US08987265B2 Substituted 1,3,5-triazine derivatives of fused bicyclic oxalamide compounds for treatment of Hepatitis C
有权
用于治疗丙型肝炎的稠合双环草酰胺化合物的1,3,5-三嗪衍生物
- Patent Title: Substituted 1,3,5-triazine derivatives of fused bicyclic oxalamide compounds for treatment of Hepatitis C
- Patent Title (中): 用于治疗丙型肝炎的稠合双环草酰胺化合物的1,3,5-三嗪衍生物
-
Application No.: US14073984Application Date: 2013-11-07
-
Publication No.: US08987265B2Publication Date: 2015-03-24
- Inventor: Tao Wang , Zhiwei Yin , Paul Michael Scola
- Applicant: Bristol-Myers Squibb Company
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agent John F. Levis
- Main IPC: A61K31/53
- IPC: A61K31/53 ; C07D251/52 ; C07D487/04 ; A61K45/06
Abstract:
Compounds of Formula I, including pharmaceutically acceptable salts thereof, as well as compositions containing these compounds, have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV:
Public/Granted literature
- US20140134130A1 FUSED BICYCLIC OXALAMIDE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C Public/Granted day:2014-05-15
Information query
